Employees: 2,301
Size Innova Captab (INNOVACAP.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $645M, the 755th largest of 1,066 India companies the cockpit tracks. Shares closed at ₹1,050 on 18 Nov 2026.
Performance Over six months the shares gained 20.2%, against -17.8% for the median peer and +3.8% for the India market (cap-weighted) — 2nd highest of 21 in its peer set.
Growth Revenue grew 36.8% over the last twelve months (peer median +10.2%); the operating margin is 12.4% (peer median 9.6%).
Valuation It trades at 32.2× forward earnings against a peer median of 24.9× (4th most expensive of 8).
Price implies For today's price to make sense, revenue must grow about 27% a year for seven years (Req g). Recent delivered growth is +31%, so the hurdle is -4 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 0.6 points above its cost of capital (11.6% WACC).
Next results Next results expected around 16 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₹18.7B | ₹16.1B | ₹12.4B | ₹10.8B | ₹9.26B |
| Revenue growth | — | +30% | +15% | +16% | — |
| Gross profit | ₹4.19B | ₹2.45B | ₹2.12B | ₹1.87B | ₹1.39B |
| EBITDA | ₹2.78B | ₹2.10B | ₹1.81B | ₹1.55B | ₹1.14B |
| Net income | ₹1.69B | ₹1.43B | ₹1.27B | ₹943M | ₹680M |
| Free cash flow | n/a | ₹341M | -₹1.06B | -₹1.53B | -₹238M |
| Capital expenditure | n/a | ₹683M | ₹1.72B | ₹2.87B | ₹790M |
| Total debt | ₹3.55B | ₹3.44B | ₹3.38B | ₹2.45B | ₹2.37B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | INNOVACAP.NS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +4.8% | -9.2% | 3rd highest of 21 |
| 6-month return | +20.2% | -17.8% | 2nd highest of 21 |
| Distance from 52-week high | -22.4% | -38.7% | 6th highest of 21 |
| Revenue growth (TTM) | +36.8% | +10.2% | 5th highest of 18 |
| Operating margin | 12.4% | 9.6% | 7th highest of 17 |
| Forward P/E | 32.2× | 24.9× | 4th most expensive of 8 |
| Growth the price implies (Req g, 7 yrs) | 27.1% | 10.1% | 3rd most demanding of 10 |
| Growth delivered (Del g) | +31.4% | +7.9% | highest of 10 |
| Hurdle (Req g minus delivered) | -4.3 pp | +12.0 pp | 3rd least demanding of 10 |
| ROIC minus cost of capital | +0.6 pp | -3.9 pp | 3rd highest of 14 |
| EV / EBITDA | 22.7× | 6.2× | 2nd most expensive of 7 |
| Net debt / EBITDA | 0.9× | -0.8× | 3rd most indebted of 8 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Innova Captab INNOVACAP.NS | India | $645M | +20% | +37% | 12% | 32.2× | 27.1% | +31.4% |
| Hainan Haiyao 000566.SZ | China | $642M | -18% | -18% | -50% | n/a | n/a | n/a |
| Beijing Beilu Pharmaceutical 300016.SZ | China | $641M | -19% | +23% | 11% | 79.7× | 9.1% | +7.9% |
| Center Laboratories 4123.TWO | Taiwan | $639M | -29% | +14% | 9% | n/a | 36.3% | +16.2% |
| FDC FDC.NS | India | $653M | +3% | +10% | 14% | n/a | 25.2% | +10.3% |
| Zhejiang Wecome Pharmaceutical 300878.SZ | China | $632M | -18% | +92% | -41% | n/a | n/a | n/a |
| Sun Pharma Advanced Research SPARC.NS | India | $660M | +6% | +3,141% | 84% | n/a | n/a | n/a |
| Arbutus Biopharma ABUS | United States | $630M | -6% | +1,143% | 80% | n/a | n/a | n/a |
| Bicara Therapeutics BCAX | United States | $623M | -54% | n/a | n/a | n/a | n/a | n/a |
| Annexon ANNX | United States | $671M | -30% | n/a | n/a | n/a | n/a | n/a |
| Jiangsu Aidea Pharmaceutical 688488.SS | China | $672M | -35% | +7% | 8% | 112.1× | 31.9% | +19.8% |
| Philogen PHIL.MI | Italy | $672M | -11% | +295% | 79% | 10.1× | n/a | n/a |
| Hubei Biocause Heilen Pharmaceutical 301211.SZ | China | $619M | -10% | +13% | 4% | n/a | n/a | n/a |
| Olema Pharmaceuticals OLMA | United States | $619M | -49% | n/a | n/a | n/a | n/a | n/a |
| Youcare Pharmaceutical 688658.SS | China | $674M | -49% | -7% | -13% | 24.9× | n/a | n/a |
| TTY Biopharm 4105.TWO | Taiwan | $615M | +10% | +5% | 29% | 10.2× | -8.7% | +8.8% |
| Yabao Pharmaceutical 600351.SS | China | $678M | 0% | -3% | 16% | n/a | -8.3% | -2.8% |
| Orchid Pharma ORCHPHARMA.NS | India | $613M | +30% | +11% | 0% | 83.1× | n/a | n/a |
| Fuan Pharmaceutical (Group) 300194.SZ | China | $612M | -14% | -3% | -1% | n/a | 10.9% | -5.9% |
| Zhejiang Anglikang Pharmaceutical 002940.SZ | China | $612M | -52% | -13% | 10% | n/a | 10.1% | +2.1% |
| HeiLongJiang ZBD Pharmaceutical 603567.SS | China | $610M | -39% | -82% | n/a | 5.4× | 9.1% | -25.1% |